Alzheimer's Disease, Familial, Plus APOE Panel
Use
This test is intended for individuals who have relevant features or a clinical or suspected diagnosis of familial Alzheimer's disease, as well as those with a family history of Alzheimer's disease. It aids in the detection of genetic variations that may contribute to Alzheimer's disease, allowing for better understanding and management of the condition.
Special Instructions
Specimen requirements vary depending on the platform used. Blood, DNA, buccal, saliva, and tissue specimens are accepted for the exome platform, while blood and DNA are accepted for the genome platform. STAT testing is available for faster turnaround, with a surcharge applied.
Limitations
This test cannot detect all genetic variations associated with Alzheimer's disease. Variants of unknown significance may be found, and not all pathogenic variants are detectable with NGS and CNV analysis. The test's sensitivity and specificity depend on the quality of the DNA sample and coverage achieved during sequencing.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided